Jessica Wiley, Author at ELIAS Animal Health

ELIAS Animal Health featured on Worldwide Business with kathy ireland®

Olathe, Kan., May 15, 2019 – ELIAS Animal Health, a Kansas City company dedicated to improving the treatment options for companion animals diagnosed with cancer, will be featured on Worldwide Business with kathy ireland®. Distributed internationally as sponsored content, you can view a highlight video below. The full interview will air on the following channels: Americas: Fox Business Network May 19, 2019, 5:30 p.m. EST Europe & Africa: Bloomberg EMEA Saturday, May 18, 2019, 7:30 p.m. GMT Asia: Bloomberg Asia Sunday, May 19, 2019, 10:30 a.m. D.F. and 3:00 p.m. HKT

By Jessica Wiley|2019-06-11T21:23:44-06:00May 16th, 2019|Categories: Press Releases|Tags: cancer immunotherapy, canine cancer|0 Comments

Companion animal access to immunotherapy treatments trails human medicine

Immunotherapy treatments are a hot topic in the area of treating human malignancies, which begs the question in the minds of many pet owners whose dogs or cats are diagnosed with cancer: where are these therapies for the four-legged members of the family? There are several barriers to making immunotherapies available in the veterinary space. However, a recent article in Veterinary Practice News by Hans Klingemann, MD, PhD, details some of these challenges and highlights the work being done by ELIAS Animal Health to overcome such barriers. “While patient survival outcomes using traditional cancer therapies such as chemotherapy and radiation have not significantly changed in the past couple of decades, they still remain the proven standard of care used by veterinary oncologists,” said Noe Reyes, Chief Medical Officer for ELIAS. “There is a significant unmet need for safer and more effective therapies to treat cancer. Immunotherapies, including adoptive T cell [...]

By Jessica Wiley|2022-08-04T18:47:53-06:00May 14th, 2019|Categories: Blog|Tags: autologous prescription product, cancer immunotherapy, canine osteosarcoma|0 Comments

University announces advancement in canine cancer treatment

The University of Missouri recently shared progress on their work in helping advance ELIAS Animal Health’s treatment for bone cancer in dogs. The canine immunotherapy treatment is now available at MU, as well as at other universities and specialty hospitals across the country. Dr. Jeff Bryan, director of the MU's Comparative Oncology and Epigenetics Laboratory and principal investigator of the clinical trial, said of the treatment, “It’s the first time that dogs with osteosarcoma have experienced prolonged survival without receiving chemotherapy, which is really exciting.” Read the full announcement.

By Jessica Wiley|2020-02-26T15:08:42-06:00March 3rd, 2019|Categories: News|Tags: cancer immunotherapy, canine cancer, canine osteosarcoma, university of missouri|0 Comments

Percentage of pets covered by insurance continues to grow

One in four dogs will be diagnosed with cancer in their lifetimes, and that’s only one of many diseases that can present a pet owner with a difficult health decision for their pet. This article highlights that an increasing number of pet owners are choosing to mitigate the financial challenges inherent in advanced treatments by purchasing pet insurance. According to Sarah A. Moser in a recent DVM360 article, the percentage of pets covered by insurance continues to grow, and looks to be accelerating with the millennial generation owning an ever increasing percent of total dogs and cats. Our inquiries indicate that ECI® from ELIAS is covered by many insurance companies today, when prescribed by a veterinarian. veterinarybusiness.dvm360.com/future-trend-millennials-could-be-boost-pet-insurance-needs

By Jessica Wiley|2022-08-04T18:48:00-06:00January 15th, 2019|Categories: Blog|0 Comments

ELIAS Animal Health Announces Positive Results in Treatment of Osteosarcoma in Dogs

Olathe, Kan., Oct. 25, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, announced results from its canine osteosarcoma immunotherapy trial at the 2018 Veterinary Cancer Society (VCS) Annual Conference. The study evaluating ELIAS’ Autologous Prescription Product, known as ELIAS Cancer Immunotherapy (ECI®) resulted in a median survival time (MST) of 415 days in animals completing therapy – compared to historical treatment outcomes associated with surgery alone (134 days). These results will be included in the ELIAS submission to USDA-CVB during the fourth quarter. ELIAS intends to initiate a larger field safety and efficacy study in early 2019. “We are very encouraged by our osteosarcoma clinical trial results as we move towards commercialization of ECI® for the veterinary community, while continuing to explore our platform technology in other cancers such as lymphoma,” said Noe Reyes, D.V.M., ELIAS medical director. The trial [...]

By Jessica Wiley|2022-08-04T18:47:03-06:00October 25th, 2018|Categories: Press Releases|Tags: canine cancer, canine osteosarcoma, results|0 Comments

ELIAS autologous prescription product exceeds expectations for trial safety and efficacy

Olathe, Kan., July 31, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, shared promising preliminary canine osteosarcoma results for its cancer immunotherapy at the 2018 American College of Veterinary Internal Medicine (ACVIM) Forum in June. The study indicated its new ELIAS autologous cancer vaccine, featuring a patented combination of vaccine and T cell infusion approach, demonstrated impressive survival times and minimal side effects. This cancer immunotherapeutic is being distributed as an experimental product under 9 CFR 103.3 to veterinarians treating dogs diagnosed with cancer. Efficacy and safety have not been established. The results were presented by Brian Flesner, D.V.M., Dipl. ACVIM-Oncology, University of Missouri, and highlight continued progress within the immunotherapy arena for the treatment of canine cancer. One in four dogs will be impacted by cancer in their lifetimes and cancer is the No. 1 cause of death in [...]

By Jessica Wiley|2020-02-26T15:09:41-06:00July 31st, 2018|Categories: Press Releases|Tags: autologous prescription product, canine cancer|0 Comments

ELIAS Animal Health Cancer Immunotherapy selected for state of the art presentation at VCS Mid‐Year Conference

Olathe, Kan., Feb. 12, 2018 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, has been selected by the Veterinary Cancer Society (VCS) for a “State of the Art” presentation at its Mid‐Year Conference in Anchorage, Alaska, March 10‐13. The mid‐year conference is focused on immunotherapy. Brenda Phillips, D.V.M., Dipl. ACVIM (Oncology) will present “T cell‐mediated immunotherapy for common canine cancers” during the state of the art presentation on Sunday, March 11. Dr. Phillips is a board‐certified specialist in medical oncology, practicing with Veterinary Specialty Hospital in San Diego, Calif. The clinical process, ongoing trials, management and experiences of this treatment being developed specifically for veterinary use in dogs will be discussed during the 30‐minute presentation. More data from the study is expected to be presented at the ACVIM Forum in June. ELIAS Animal Health has applied for conditional licensure of its [...]

By Jessica Wiley|2020-02-26T15:10:20-06:00February 12th, 2018|Categories: Press Releases|Tags: canine cancer|0 Comments

ELIAS Animal Health adds clinical trial site for ECI™ for the treatment of canine osteosarcoma

ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, is offering a fourth site for its clinical trial to determine the safety and efficacy of ELIAS Cancer Immunotherapy (ECI™) as a treatment for newly- diagnosed appendicular osteosarcoma in dogs. The objective of this clinical trial is to determine whether ECI™ used in combination with surgery produces better outcomes than treatment with surgery alone. Efficacy will be determined by patient survival and comparing the outcomes to historical control data. The trial will be conducted at the Veterinary Specialty Hospital of San Diego. ELIAS Animal Health chief executive officer, Tammie Wahaus, shared a promising update on trial results to-date on Nov. 3, during the Collaborate2Cure series sponsored by Kansas City Area Life Sciences Institute and BioKansas. “Early clinical study results already show positive outcomes,” said Wahaus. “One patient, a 6-year old German Shorthaired Pointer, has [...]

By Jessica Wiley|2020-02-26T15:10:43-06:00November 15th, 2016|Categories: Press Releases|0 Comments

First patient enrolled in ELIAS clinical trial for treatment of canine b-cell lymphoma

Olathe, Kan., Aug. 24, 2016 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a clinical trial to determine the safety and efficacy of ELIAS Cancer Immunotherapy (ECI™), as a treatment for B-cell lymphoma in dogs. The majority of canine lymphomas are derived from B cells. While lymphoma is one of the most responsive cancers to chemotherapy, permanent cures in dogs are extremely rare and remissions are short-lived. There is a need for safer, more effective treatments for this disease. The objective of this clinical trial is to determine whether ECI™ used in combination with chemotherapy produces better outcomes than treatment with chemotherapy alone. Efficacy will be determined by patient survival and comparing the outcomes to historical control data. The trial will be conducted at the Kansas State University Veterinary Health Center. The ECI™ treatment protocol vaccinates [...]

By Jessica Wiley|2020-02-26T15:12:02-06:00August 24th, 2016|Categories: Press Releases|0 Comments

ELIAS Animal Health names Ronald Schultz and Noe Reyes to Scientific Advisory Board

Olathe, Kan., September 1, 2015 - ELIAS Animal Health, a clinical stage development company advancing novel targeted T cell-based immunotherapy for the treatment of cancer in companion animals, today announced it has filled the remaining appointments to the company’s scientific advisory board with the additions of Ronald Schultz, PhD, and Noe Reyes, DVM. They join board chair Kevin Schultz, DVM, PhD, and Ralph Richardson, DVM, on the advisory board, which is tasked with offering strategic guidance on the advancement of therapies in development and exploring new therapeutic areas in which the company’s technology would be applicable. Dr. Ron Schultz is a recognized leader on veterinary vaccines, virology and immunology. He currently serves as professor and chair of the Department of Pathobiological Sciences at the School of Veterinary Medicine at the University of Wisconsin-Madison. His primary emphasis of research focuses on the pathogenesis of viral infections in large and companion animals. [...]

By Jessica Wiley|2020-02-26T15:12:20-06:00September 1st, 2015|Categories: Press Releases|0 Comments

About Jessica Wiley